239 related articles for article (PubMed ID: 29444439)
1. Differential Effector Engagement by Oncogenic KRAS.
Yuan TL; Amzallag A; Bagni R; Yi M; Afghani S; Burgan W; Fer N; Strathern LA; Powell K; Smith B; Waters AM; Drubin D; Thomson T; Liao R; Greninger P; Stein GT; Murchie E; Cortez E; Egan RK; Procter L; Bess M; Cheng KT; Lee CS; Lee LC; Fellmann C; Stephens R; Luo J; Lowe SW; Benes CH; McCormick F
Cell Rep; 2018 Feb; 22(7):1889-1902. PubMed ID: 29444439
[TBL] [Abstract][Full Text] [Related]
2. Mapping Effector-Phenotype Landscapes in KRAS-Driven Cancers.
Winter PS; Wood KC
Trends Cancer; 2018 May; 4(5):333-335. PubMed ID: 29709255
[TBL] [Abstract][Full Text] [Related]
3. The GTPase KRAS suppresses the p53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cells.
Yang H; Xiang S; Kazi A; Sebti SM
J Biol Chem; 2020 Mar; 295(10):3055-3063. PubMed ID: 32001619
[TBL] [Abstract][Full Text] [Related]
4. The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells.
Hoang VT; Nyswaner K; Torres-Ayuso P; Brognard J
J Biol Chem; 2020 Jun; 295(25):8470-8479. PubMed ID: 32358059
[TBL] [Abstract][Full Text] [Related]
5. MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival.
Lee CS; Lee LC; Yuan TL; Chakka S; Fellmann C; Lowe SW; Caplen NJ; McCormick F; Luo J
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4508-4517. PubMed ID: 30709910
[TBL] [Abstract][Full Text] [Related]
6. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction.
Ito RE; Oneyama C; Aoki K
PLoS One; 2021; 16(4):e0249388. PubMed ID: 33793658
[TBL] [Abstract][Full Text] [Related]
8. Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas.
Li J; Sordella R; Powers S
Sci Rep; 2016 Jun; 6():27891. PubMed ID: 27301828
[TBL] [Abstract][Full Text] [Related]
9. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
[TBL] [Abstract][Full Text] [Related]
10. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
11. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
Yurugi H; Marini F; Weber C; David K; Zhao Q; Binder H; Désaubry L; Rajalingam K
Oncogene; 2017 Aug; 36(33):4778-4789. PubMed ID: 28414306
[TBL] [Abstract][Full Text] [Related]
12. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.
Xu K; Park D; Magis AT; Zhang J; Zhou W; Sica GL; Ramalingam SS; Curran WJ; Deng X
Mol Cancer; 2019 Apr; 18(1):85. PubMed ID: 30971271
[TBL] [Abstract][Full Text] [Related]
13. Targeting the KRAS, p38α, and NF-κB in lung adenocarcinoma cancer cells: The effect of combining RNA interferences with a chemical inhibitor.
Zarredar H; Pashapour S; Farajnia S; Ansarin K; Baradaran B; Ahmadzadeh V; Safari F
J Cell Biochem; 2019 Jun; 120(6):10670-10677. PubMed ID: 30656741
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic activating mutations are associated with local copy gain.
Modrek B; Ge L; Pandita A; Lin E; Mohan S; Yue P; Guerrero S; Lin WM; Pham T; Modrusan Z; Seshagiri S; Stern HM; Waring P; Garraway LA; Chant J; Stokoe D; Cavet G
Mol Cancer Res; 2009 Aug; 7(8):1244-52. PubMed ID: 19671679
[TBL] [Abstract][Full Text] [Related]
15. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
16. Synthetic Lethal Vulnerabilities in
Aguirre AJ; Hahn WC
Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29101114
[TBL] [Abstract][Full Text] [Related]
17. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
Park KS; Yang H; Choi J; Seo S; Kim D; Lee CH; Jeon H; Kim SW; Lee DH
Cancer Lett; 2017 Oct; 406():47-53. PubMed ID: 28797845
[TBL] [Abstract][Full Text] [Related]
18. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
19. Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown.
Srikar R; Suresh D; Zambre A; Taylor K; Chapman S; Leevy M; Upendran A; Kannan R
Sci Rep; 2016 Aug; 6():30245. PubMed ID: 27530552
[TBL] [Abstract][Full Text] [Related]
20. Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.
Fritsche-Guenther R; Witzel F; Kempa S; Brummer T; Sers C; Blüthgen N
Oncotarget; 2016 Feb; 7(7):7960-9. PubMed ID: 26799289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
